(Total Views: 410)
Posted On: 09/29/2019 9:43:59 AM
Post# of 153935
Re: Nt2innvovate #8942
Nt2 , - I will agree with you except that our combo and not mono is for unmet need,
To be in mono patient must have VL < 50 copies /ml.
as our combo is for MDR 2 and 3 patients ,
and the only competition with efficacy of 45% and severe side effects is Maraviroc for MDR 2 and 3,
and for MDR 3 IV Ibalizumab with 43% efficacy and some side effects.
Our combo is an emergency , and it is not treated like that by FDA.!!!!!!
and IMO this is a big problem .....
I am curious what will happen with BTD.
IMO as always.
To be in mono patient must have VL < 50 copies /ml.
as our combo is for MDR 2 and 3 patients ,
and the only competition with efficacy of 45% and severe side effects is Maraviroc for MDR 2 and 3,
and for MDR 3 IV Ibalizumab with 43% efficacy and some side effects.
Our combo is an emergency , and it is not treated like that by FDA.!!!!!!
and IMO this is a big problem .....
I am curious what will happen with BTD.
IMO as always.
(1)
(0)
